Recently Active Investors

Amplexd Therapeutics focuses on the development of non-invasive, topical treatments aimed at addressing HPV-induced cervical dysplasia, a precursor to cervical cancer. The company's mission centers on providing accessible solutions to combat this public health issue, offering alternatives to the traditional 'watch and wait' approachfor low-grade cases.

4P-Pharma specializes in the development of therapeutics that offer treatment for osteoarthritis with analgesic and anti-inflammatory properties.

Clock.bio aims to extend and improve quality of life by reversing the harmful effects of time in our cells, harnessing the regenerative capabilities of human pluripotent stem cells.

SciTech Development provides pharmaceuticals comprising nanoparticle fenretinide formulation with immunotherapy benefits, as well as a patented nanoparticle delivery technology, allowing physicians to treat their patients with effective and advanced therapies.

Micreos is a company that creates phage technology for selective bacterial control in Wageningen, Netherlands. It creates the first tailored antibacterial products in the world, which will displace antibiotics.

Digitalis is a venture capital firm that invests in complicated human and animal health concerns. It collaborates with business owners, scientists, and inventors at all stages of the venture investing process, and our investments cover the whole healthcare ecosystem.

Genoa Ventures is a venture capital firm that invests in early-stage life sciences technology companies.

ARCH is an early-stage venture firm that focuses on life science discoveries to prevent, detect, and cure disease.

Forbion Capital Partners is a private equity and venture capital firm for making investments in buyouts.

Investing in the future of food.

Catalio Capital Management is a Venture capital investments in breakthrough biomedical technology companies.

Teclison is to develop new drugs to treat cancer and other diseases with strong unmet medical needs.

Omega Funds global life sciences-based investment firm specialized in direct secondary transactions.